Benzodiazepines: Effective Medications for Anxiety That Can Cause Dependence

Benzodiazepines are a group of medications that act on the central nervous system. They have anxiolytic, sedative, hypnotic, anticonvulsant, and muscle-relaxant properties. Some of the best-known medications include alprazolam (Xanax, Afobam), diazepam (Relanium), lorazepam (Lorafen), clonazepam, and bromazepam (Lexotan). Their mechanism of action involves enhancing the effects of gamma-aminobutyric acid (GABA), one of the most important neurotransmitters responsible for inhibiting nerve cell activity. Benzodiazepines enhance the action of GABA at GABA-A receptors, thereby reducing nervous system excitability. Patients may experience relaxation, reduced anxiety, relief from tension, and drowsiness. The onset and duration of action depend on the specific medication, dose, and route of administration.

These medications play an important role in modern medicine. They are used, among other indications, for the short-term treatment of severe anxiety, selected medical emergencies, certain types of epileptic seizures, and alcohol withdrawal syndrome. One of their main advantages is their relatively rapid onset of action, particularly compared with antidepressants used to treat anxiety disorders. However, benzodiazepines are generally not recommended as the primary long-term treatment for chronic anxiety disorders because regular use carries a risk of developing tolerance, physical dependence, and substance use disorder.

One mechanism contributing to problematic benzodiazepine use is the rapid improvement in how a person feels. Someone experiencing severe anxiety may notice that their symptoms decrease significantly after taking a tablet. The brain begins to associate taking the medication with relief from distressing symptoms, which may reinforce the tendency to use it again in stressful situations. At the same time, with regular use, the nervous system gradually adapts to the presence of the substance. These changes may lead to the development of tolerance and physical dependence. The level of risk depends on several factors, including the dose, duration of treatment, type of benzodiazepine, and individual patient susceptibility.

It is important to distinguish between three concepts that are often confused: tolerance, physical dependence, and addiction. Tolerance refers to a reduction in a particular effect of a medication following repeated use. A patient may notice that a dose that previously produced significant calming effects or drowsiness becomes less effective over time. However, tolerance does not necessarily develop equally to all effects of benzodiazepines. Physical dependence, on the other hand, involves the body’s adaptation to the presence of the medication. If the drug is suddenly discontinued or its dose is reduced too quickly, withdrawal symptoms may occur. Addiction, clinically understood as a substance use disorder, involves factors such as loss of control over medication use, difficulty reducing consumption, and continued use despite significant harm. Therefore, a patient may develop physical dependence without meeting the diagnostic criteria for addiction.

Importantly, regular use of benzodiazepines at therapeutic doses can lead to physical dependence even when patients strictly follow their doctor’s instructions. In some individuals, dependence may develop after just a few weeks of treatment. This does not automatically mean that the patient is addicted in the psychiatric sense. A person may not independently increase their dose, seek additional prescriptions, or exhibit behaviors characteristic of substance use disorder, yet still experience withdrawal symptoms when attempting to stop treatment. For this reason, long-term benzodiazepine therapy requires regular assessment of its benefits and risks.

There is no single dose or specific number of days after which every patient will develop dependence. The risk increases particularly with daily, long-term use, higher doses, and independently modifying the prescribed dosage. Warning signs may include taking benzodiazepines increasingly frequently, needing a higher dose to achieve a similar effect, or experiencing intense anxiety at the thought of not having access to the medication. Using the medication for purposes other than those prescribed, such as improving mood or coping with every difficult emotion, is also concerning. However, regular use over an extended period does not automatically establish a diagnosis of addiction, which requires an individual clinical assessment.

Abruptly stopping regular benzodiazepine use can lead to withdrawal syndrome. Patients may experience increased anxiety, restlessness, irritability, insomnia, hand tremors, excessive sweating, palpitations, difficulty concentrating, increased sensitivity to sound and light, and gastrointestinal symptoms. In more severe cases, disturbances of consciousness, hallucinations, and even seizures may occur. Suddenly discontinuing benzodiazepines in a person who has developed physical dependence can be dangerous and potentially life-threatening. Seizures, severe confusion, or disturbances of consciousness require urgent medical attention. The timing of withdrawal symptoms depends, among other factors, on the medication’s elimination half-life. Symptoms may appear earlier with shorter-acting medications than with longer-acting ones, and in some patients they may persist for an extended period.

A deterioration in well-being after reducing a benzodiazepine dose does not always indicate a relapse of the original condition. It may be associated with withdrawal syndrome or a so-called rebound effect, meaning a temporary intensification of symptoms previously suppressed by the medication. Factors that help distinguish these situations include the timing of symptom onset, their characteristics, the course of previous treatment, and the presence of additional withdrawal symptoms. Therefore, increased anxiety following a dose reduction should not automatically lead to the conclusion that the patient must take benzodiazepines for the rest of their life.

Combining benzodiazepines with alcohol is another significant risk. Both substances depress the central nervous system, so taking them together can cause severe coordination problems, drowsiness, memory impairment, and a substantial reduction in judgment. In severe cases, respiratory depression, loss of consciousness, and other serious complications may occur. Combining benzodiazepines with opioids is particularly dangerous because it increases the risk of respiratory depression and overdose. Patients should avoid alcohol during treatment and should not independently combine benzodiazepines with other sedative medications.

Benzodiazepines can also affect memory, concentration, and psychomotor performance. In some patients, they cause impaired attention, slower reaction times, coordination difficulties, and problems forming new memories. One characteristic adverse effect is anterograde amnesia, which involves difficulty remembering events occurring after taking the medication. This is particularly important in older adults, in whom benzodiazepines also increase the risk of falls and fractures. The effects of long-term use on cognitive function are more complex and depend on numerous factors. Benzodiazepine use should not automatically be equated with the development of dementia.

Safely discontinuing treatment primarily requires avoiding abrupt withdrawal in patients who may have developed physical dependence. Dose reduction should be planned individually, taking into account the current dose, duration of use, type of medication, coexisting medical conditions, and previous attempts to discontinue treatment. The 2025 guidelines from the American Society of Addiction Medicine (ASAM) indicate that, for many patients, an initial tapering rate may involve reducing the current daily dose by approximately 5 to 10% every 2 to 4 weeks, generally not exceeding a 25% reduction over two weeks. However, this is not a universal schedule, and some patients require a considerably slower approach. In selected cases, a doctor may consider switching to a longer-acting benzodiazepine to facilitate gradual dose reduction. Discontinuation may take weeks, months, or even longer in some patients. The pace should be adjusted according to treatment tolerance and emerging symptoms. Patients should not independently begin reducing their dose based on general schedules found online.

For many chronic anxiety disorders, the foundation of long-term treatment is psychotherapy, particularly cognitive behavioral therapy (CBT), combined with appropriately selected pharmacotherapy when indicated. Depending on the diagnosis, a doctor may recommend antidepressants from the selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) groups, which are also used to treat anxiety disorders. Unlike benzodiazepines, these medications generally do not provide immediate relief from anxiety, but they can effectively reduce symptoms during long-term treatment. Treatment selection depends on the type of disorder, severity of symptoms, previous treatments, and individual medication tolerance.

Benzodiazepines remain valuable medications that can provide rapid and significant relief when used for appropriate indications. However, their effectiveness does not mean they are free from risks. Responsible and medically supervised use is particularly important when treatment continues longer than originally planned. The development of physical dependence is not equivalent to addiction, but it requires caution when ending treatment. Properly planned, gradual withdrawal, together with treatment of the underlying condition, allows many patients to discontinue benzodiazepines safely.

Patient FAQ:

References: